Correlation between percentage of fat mass and level of disease activity in rheumatoid arthritis

Guadalupe Mendoza-Vázquez¹,², Francisco Espinoza-Gómez², Alberto Daniel Rocha-Muñoz³, Jorge I. Gamez-Nava¹,⁴, Laura Gonzalez-Lopez⁴, Mario Salazar-Paramo⁵, Carlos Riebeling-Navarro⁶,⁷, Javier Alejandro Aceves-Aceves¹,⁴, Sandra Guzmán-Silahua¹,⁴,¹⁰ and Arnulfo Hernán Nava-Zavala¹,⁸,⁹

Abstract
Introduction: Controversies exist regarding the relationship between body fat and disease activity in patients with rheumatoid arthritis. The evaluation of the disease is critical for establishing treatment and prognosis. Fat mass could be a predictive factor for poor prognosis in rheumatoid arthritis because of its association with low- and high-grade inflammation.
Objective: To evaluate the correlation between fat mass values and disease activity in patients with rheumatoid arthritis.
Materials and methods: This was a cross-sectional study. Eighty female patients diagnosed with rheumatoid arthritis (American College of Rheumatology of 1987) were evaluated. For each one, the evaluation determined fat mass using bioelectrical impedance analysis and disease activity using the Disease Activity Score on 28 joints (DAS28).
Results: The mean age was 59.11 ± 9.92 years, with an average disease duration of 14.13 ± 10.13 years; 85% of patients showed a high body fat percentage. Pearson’s correlation between DAS28 values and fat mass was r = 0.035 (p = 0.76).
Conclusion: The levels of DAS28 showed no correlation with fat mass percentage. Further studies are required to clarify the factors that can modify these levels.
Keywords
Rheumatoid arthritis, body mass index, fat mass, chronic disease, DAS28

Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease. In addition to symptoms in the joints, the disease can be related to changes in body composition, such as obesity and rheumatoid cachexia, especially when the disease is active.¹,² RA is one of the most frequent autoimmune diseases with a prevalence of 1.3% worldwide; in Latin America, it ranges related to changes in body composition, such as obesity and rheumatoid cachexia, especially when the disease is active.¹,²

¹Unidad de Investigación Epidemiológica y en Servicios de Salud y Unidad de Investigación Biomédica 02, Unidad Médica de Alta Especialidad, Hospital de Especialidades, Centro Médico Nacional del Seguro Social, Guadalajara, México
²Programa de Doctorado en Ciencias Médicas, Facultad de Medicina, Universidad de Colima, Colima, México
³Centro Universitario de Tonalá, Universidad de Guadalajara, Tonalá, México
⁴Programa de Doctorado en Farmacología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, México
⁵Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, México
⁶Unidad de Investigación en Epidemiología Clínica, Unidad Médica de Alta Especialidad, Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México
⁷Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, México
⁸Programa Internacional, Facultad de Medicina, Universidad Autónoma de Guadalajara, Zapopan, México
⁹Departamento de Inmunología y Reumatología, Hospital General de Occidente, Secretaría de Salud Jalisco, Zapopan, México
 tenth author: Arnulfo Hernán Nava-Zavala, Unidad de Investigación Epidemiológica y en Servicios de Salud y Unidad de Investigación Biomédica 02, Unidad Médica de Alta Especialidad, Hospital de Especialidades, Centro Médico Nacional de Occidente, OOAD Jalisco, Instituto Mexicano del Seguro Social, Guadalajara, México.
 Corresponding author: Arnulfo Hernán Nava-Zavala, navazava@yahoo.com.mx

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
from 0.4% to 1.6%, and, in Mexico, 1.6% of the population is affected.3–5

Body weight and body mass index (BMI) may contribute to the high disability risk associated with RA.6,7 Regulation of body weight in RA patients is a complex issue6 because overweight and obesity are states of low-grade chronic inflammation associated with a diminution in physical capacities, increased pain, comorbidities, and increased inflammation markers.2,9 Therefore, it is important to assess body composition to achieve a greater understanding of the physiology of these changes and the general clinical conditions of these patients by means of a combination of anthropometric measurements (including height, weight, BMI, waist circumference, percentage of fat mass (FM), hip circumference (HC), and waist-to-hip index), dual X-ray absorptiometry (DXA), and bioelectrical impedance analysis (BIA).10–11

A high BMI is associated with radiographic joint damage that is less severe in the early stages of the disease as well as decreased mortality related to cardiovascular disease. Hence, a high BMI is considered a protective factor.8 In contrast, body composition alterations, such as obesity and FM, are associated with worse results.9,12,13 However, a lower BMI is associated with lower survival,8 which indicates a bidirectional relationship between changes in body weight and disease activity in RA patients.

Nevertheless, BMI is only an approximate measurement of body fat, and it does not detect all individuals with increased body fat.2 Adipose tissue is considered an active organ that sends and responds to a wide range of biological signals.14 Likewise, systemic inflammation starts with excess adiposity along with other factors such as smoking.15 However, high-degree inflammation in RA coexists with a higher accumulation of FM and a reduced lean mass (LM).15

In RA, the main objectives of the existing diverse therapeutic strategies are to attain disease remission (a state in which neither inflammatory activity nor progression of the structural damage exists) or a low level of clinical activity. The evaluation of disease activity is of fundamental importance for therapeutic decision-making and the establishment of a prognosis for patients with this disease.16 Every patient’s necessary goal is to control their disease activity in order to improve their symptoms, diminish their joint damage, prevent functional limitations, and improve their quality of life.17

It is desirable to count individualized predictors of the course of a disease. In addition to the determination of the autoantibodies of a disease, the rheumatoid factors, and the antibodies against cyclic citrullinated peptides, other diverse factors can predict the development of more severe diseases. These include advanced age at the onset of disease, female sex, smoking, genetics, degree of physical disability, and early erosive disease.2 Hence, predicting future clinical results based on these factors could help optimize disease management.2,18

The association of factors such as body fat and BMI with the clinical course of RA is still a debated issue, and the clinical applications of the currently available data are not entirely clear. Consequently, little is known about adiposity in rheumatic disease.2,5 Our objective was to evaluate the specific correlation between body fat percentage and RA disease activity.

Material and methods

Study design

This is a cross-sectional study.

Study population

Eighty incident and prevalent female patients aged ≥18 years diagnosed with RA according to the criteria of the American College of Rheumatology of 1987 (ACR87)16 were studied. The inclusion period was 18 months. Patients were cared for in the Unidad de Investigación Biomédica 02 in the Unidad Médica de Alta Especialidad, Hospital de Especialidades Centro Medico Nacional de Occidente IMSS. Patients excluded were those with chronic infections, cancer, thyroid disease, psychiatric diseases, and pregnancy.

Disease characteristics

A rheumatologist examined the patients. Information was recorded according to clinical and demographic characteristics, board-certified time of disease duration (years), and disease activity defined by the Disease Activity Score on 28 joints (DAS28)2 (permission was requested online at https://www.das-score.nl/en/useful-links and https://eprovide.mapi-trust.org/, which allow for direct use of the instrument for academic purposes). In addition, DAS28 scores were classified as follows: disease remission (<2.6), low disease activity (2.6–<3.2), moderate activity (3.2–<5.1), and high activity (>5.1).20 The use of disease-modifying anti-rheumatic drugs (DMARDs), glucocorticoids, non-steroidal anti-inflammatory drugs (NSAIDs), and biological agents was recorded as pharmacological therapies.

Anthropometric measurements

A trained nutritionist performed the anthropometric measurements. Evaluations included height in centimeters (cm) and weight in kilograms (kg). These were measured using a wall stadiometer graded in centimeters with a 0.5-cm accuracy (SECA 206, Hamburg, Germany) and a digital precision scale with a 0.1-kg accuracy and a scale with a range of 0–150 kg with an induction frequency of 50 kHz21 (TANITA BC-533 Inner Scan Body Composition Monitor, IL, USA), respectively. This scale also provided FM percentages. FM was measured as a percentage and dichotomized as < 30% (healthy FM) and ≥30% (high FM).22 Body weight was measured in kg, with patients wearing light clothing and no shoes, and the patients relaxed their arms next to their trunk for the foot-foot measurements (metatarsus-calcaneus).23
The patients attended the scale measurements and were instructed to: not ingest liquids in the 4 h before the test, to urinate 30 min before the test, not to perform strenuous exercise 12 h before the test, not to consume alcoholic beverages 48 h prior, not to take diuretics 7 days before the test, and not to wear metallic elements on or in their body (watches, rings, bracelets, earrings, etc.).

From the height and weight measurements, BMI values were classified according to the definition provided by the World Health Organization: low weight (<18.5 kg/m²), healthy weight (18.5–24.9 kg/m²), overweight (25.0–29.9 kg/m²), and obesity (≥30 kg/m²). Abdominal circumference was measured (cm) using a flexible fiberglass metric tape (GULICK) with a 1-mm accuracy, as established by the International Society for the Advancement of Kinanthropometry (ISAK).

Statistical analysis
Quantitative variables were described as mean value ± standard deviation, and qualitative variables were described as frequencies and percentages. Quantitative variable comparisons among groups were performed using Student’s t-test, and qualitative variables were analyzed using the chi-square test. Pearson’s correlation was used to correlate the percentages of FM with the DAS28 scores. Statistical significance was set at \( p \leq 0.05 \). Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS) for Windows version 18.

Ethical considerations
The study protocol was approved by the Ethics Committee (CLIES R-2014-1301-79). All patients signed an informed consent form.

Results
The study included 80 female patients. The average age of the patients was 59.11 ± 9.92 years, the mean weight was 66.93 ± 10.87 kg, and the mean height was 1.54 ± 0.06 m. The mean BMI of the patients was 28.17 ± 3.94 kg/m², and 58 patients were overweight or obese (72.6%). The mean percentage of FM was 36.96 ± 6.17, and 85% of the population presented a high FM percentage (>30%). Among the disease’s clinical characteristics, we found a duration time of 14.13 ± 10.13 years, with DAS28 values of 3.08 ± 1.08; 49 patients (61.3%) were classified as having active disease. Of these active patients, 24 were in the low disease activity group, 20 were in the moderate activity group, and only 5 were in the high activity group. Regarding the treatment established at the time of evaluation, 62 patients (76.3%) received glucocorticoids and 65 (81.3%) received some NSAIDs. Seventy-five patients (93.8%) were on DMARDs, and only eight patients (10%) received biological agent therapy. Complementary general characteristics are described in Table 1.

The correlation analysis between FM percentages and the examined variables showed a correlation with body composition parameters, such as BMI \((r = 0.835, p < 0.001)\), and with the waist-to-hip index (WHI) \((r = 0.281, p = 0.01)\). Table 2 shows that there was no correlation with disease characteristics.

| Table 1. Clinical-demographic characteristics of 80 women with rheumatoid arthritis (RA) at the time of inclusion in the study. |
|---------------------------------------------------------------|
| **General characteristics**                                   |
| Age, years                                                   | 59.11 ± 9.92 |
| Physical activity (30 min/day)                               |                |
| Yes                                                          | 28 (35%)     |
| No                                                           | 52 (65%)     |
| **Anthropometric characteristics**                           |
| Weight, kg                                                   | 66.93 ± 10.87|
| Height, m                                                    | 1.54 ± 0.06  |
| Body mass index (BMI kg/m²)                                  | 28.17 ± 3.94 |
| Normal (18.5–24.9 kg/m²)                                     | 22 (27.5%)   |
| Overweight (25.0–29.9 kg/m²)                                 | 29 (36.3%)   |
| Obesity (≥30 kg/m²)                                          | 29 (36.3%)   |
| Waist-to-hip index                                           | 0.88 ± 0.06  |
| Normal (0.71–0.93)                                           | 62 (77.5%)   |
| Android (>0.93)                                              | 18 (22.5%)   |
| Percentage of body fat, %                                     |                |
| Normal fat (<30%)                                            | 12 (15%)     |
| High fat (≥30%)                                              | 68 (85%)     |
| **Clinical characteristics**                                 |
| Disease duration, years                                      | 14.13 ± 10.13|
| DAS28 values                                                 | 3.08 ± 1.08  |
| Not active (remission)                                       | 31 (38.8%)   |
| Active                                                       | 49 (61.3%)   |
| Category of disease activity                                 |
| Low disease activity                                         | 24 (30%)     |
| Moderate activity                                            | 20 (25%)     |
| High activity                                                | 5 (6.3%)     |
| **Pharmacological treatment**                                |
| Use of glucocorticoids                                       | 61 (76.3%)   |
| Use of NSAIDs                                                | 65 (81.3%)   |
| Use of DISMD                                                 | 75 (93.8%)   |
| Azathioprine                                                 | 13 (16.3%)   |
| Chloroquine                                                  | 9 (11.3%)    |
| D-penicillamine                                              | 3 (3.8%)     |
| Leflunomide                                                  | 33 (41.3%)   |
| Methotrexate                                                 | 40 (50%)     |
| Sulfasalazine                                                | 24 (30%)     |
| Monotherapy                                                  | 26 (32.5%)   |
| Combined therapy                                             | 50 (62.5%)   |
| Use of biological agents                                     | 8 (10%)      |
| Etanercept                                                   | 8 (10%)      |

RA: rheumatoid arthritis; BMI: body mass index; DAS28: Disease Activity Score in 28 joints; NSAIDs: non-steroidal anti-inflammatory drugs; DISMD: disease-modifying drug. Qualitative variables are expressed as frequencies (%); quantitative variables are expressed as mean values and standard deviation.
Table 2. Correlation of FM percentage and body composition parameters with disease characteristics in 80 AR patients.

| Characteristics                  | Percentage of FM | r     | p     |
|-----------------------------------|------------------|-------|-------|
| Age, years                        |                  | 0.036 | 0.74  |
| Body composition                  |                  |       |       |
| Body mass index (BMI, kg/m²)      |                  | 0.835 | <0.001|
| Waist-to-hip index, cm            |                  | 0.281 | 0.01  |
| Disease characteristics           |                  |       |       |
| DAS28, units                      |                  | 0.035 | 0.76  |
| Disease duration, years           |                  | 0.126 | 0.26  |

BMI: body mass index; WHI: waist-to-hip index; DAS28: Disease Activity Score in 28 joints.

Table 3. Comparison of anthropometric and clinical characteristics of 80 RA patients, categorized by percentage of body fat.

| Characteristics                  | Normal (<30%) (n = 12) | High (≥30%) (n = 68) | p     |
|-----------------------------------|------------------------|----------------------|-------|
| Age, years                        | 54.33 ± 13.67          | 68 ± 8.93            | 0.07  |
| Weight                            | 55.19 ± 7.86           | 69.00 ± 10.01        | 0.001 |
| Physical activity                 | 4 (33.3%)              | 24 (35.3%)           | 1.00  |
| BMI                               | 23.26 ± 2.65           | 29.03 ± 3.48         | <0.001|
| WHI                               | 0.85 ± 0.06            | 0.89 ± 0.06          | 0.06  |
| Disease duration, years           | 11.42 ± 7.46           | 14.60 ± 10.50        | 0.31  |
| DAS28 grading                     | 2.97 ± 0.89            | 3.10 ± 1.11          | 0.70  |
| Use of glucocorticoids            | 9 (75%)                | 52 (76.5%)           | 1.00  |
| Use of NSAIDs                     | 11 (91.7%)             | 54 (79.4%)           | 0.44  |
| Use of DISMD                      | 11 (91.7%)             | 64 (94.1%)           | 0.56  |
| Azathioprine                      | 0 (0%)                 | 13 (19.1%)           | 0.19  |
| Chloroquine                       | 1 (8.3%)               | 8 (11.8%)            | 1.00  |
| Leflunomide                       | 4 (33.3%)              | 29 (42.6%)           | 0.75  |
| Methotrexate                      | 8 (66.7%)              | 32 (47.1%)           | 0.34  |
| Sulfasalazine                     | 6 (50%)                | 18 (26.5%)           | 0.16  |
| Monotherapy                       | 3 (25%)                | 23 (33.8%)           | 0.74  |
| Combined therapy                  | 8 (66.7%)              | 42 (61.8%)           | 1.00  |
| Use of BA (etanercept)            | 2 (16.7%)              | 6 (8.8%)             | 0.34  |

BMI: body mass index; WHI: waist-to-hip index; DAS28: Disease Activity Score in 28 joints; NSAIDs: non-steroidal anti-inflammatory drugs; DISMD: disease-modifying drug; BA: biological agent.

Qualitative variables are expressed as frequencies (%), and quantitative variables are expressed as mean values and standard deviations. Quantitative variables were compared using Student’s t-test for independent samples, and qualitative variables were compared using the chi-square test.

Table 3 presents a comparison between patients with healthy body fat (<30%) and those with high body fat (≥30%). Among the variables of interest, a significant difference was observed in weight (p = 0.001) and BMI (p < 0.001).

Table 4 depicts the comparison of RA characteristics according to disease activity or remission of the disease measured using the DAS28. An association was observed in patients in remission with more physical activity (p = 0.05).

Multivariate analysis was performed to assess the risk of developing a body FM >30% in terms of other plausible variables. No association was found with either the DAS28 score or with the other variables introduced in the model (Table 5).

Discussion

This study provides information on the specific correlation of disease activity, assessed using the DAS28, with percentage of FM. According to the literature review, we did not find studies in which the main objective was to determine the associations between variables capable of producing alterations in body fat. Moreover, the FM register was a descriptive variable reported among the related variables (BMI, adiposity index, waist, and WHI). In addition, the
epidemiological designs were of the longitudinal type (clinical assays or cohorts).26–32

Variables related to FM have been reported discrepantly among authors, which could be due to the fact that RA is more prevalent in women.29,33 This study provides information on these aspects in women. The data analyzed in this study agree with previous literature reports that reported patterns of low correlation values.27,29,32 Although being overweight significantly decreases the chance of achieving reasonable disease control,34,35 this pattern of low correlation values between FM percentage and DAS28 scores may be associated with the use of therapeutics (93.8% of this study population was being treated with the DMARDs regimen, whereas 10% used biological agents).29,32 Both treatment modalities have immunosuppressive effects that act by controlling the immune response; hence, they can regulate and diminish inflammation, leading to disease improvement and changing the natural history of the disease.14,36 These treatments also affect the regulation of FM and LM (an effect that has been studied scarcely in short-lasting treatments), which could be a factor that could explain the results of this study.27

However, we found that 68/80 patients had a high percentage of FM (⩾30%);22 however, we found no association between the clinical and anthropometric characteristics. No correlation was found between FM percentages and DAS28

Table 4. Comparison of anthropometric and clinical characteristics of the disease in 80 RA patients according to remission or activity measured by DAS28 scores.

| Characteristics                  | Remission (DAS28 <2.6) | Activity (DAS28 >2.6) | p  |
|----------------------------------|------------------------|-----------------------|----|
| N                                | 31                     | 49                    | NA |
| Age, years                       | 58.65 ± 12.78          | 59.41 ± 7.73          | 0.74 |
| Weight                           | 67.16 ± 9.45           | 66.78 ± 11.78         | 0.88 |
| Physical activity                | 15 (48.4%)             | 13 (26.5%)            | 0.05 |
| BMI                              | 28.07 ± 4.27           | 28.23 ± 3.77          | 0.86 |
| WHI                              | 0.88 ± 0.06            | 0.88 ± 0.06           | 0.70 |
| Disease duration, years          | 11.97 ± 9.10           | 15.49 ± 10.55         | 0.13 |
| Use of glucocorticoids           | 23 (74.2%)             | 38 (77.6%)            | 0.79 |
| Use of NSAIDs                    | 27 (87.1%)             | 38 (77.6%)            | 0.38 |
| Use of DISMD                     | 28 (90.3%)             | 47 (95.9%)            | 0.37 |
| Azathioprine                     | 4 (12.9%)              | 9 (18.4%)             | 0.75 |
| Chloroquine                      | 4 (12.9%)              | 5 (10.2%)             | 0.72 |
| Leflunomide                      | 11 (35.5%)             | 22 (44.9%)            | 0.48 |
| Methotrexate                     | 16 (51.6%)             | 24 (49%)              | 1.00 |
| Sulfasalazine                    | 10 (32.3%)             | 14 (28.6%)            | 0.80 |
| Monotherapy                      | 9 (29%)                | 17 (34.7%)            | 0.63 |
| Combined therapy                 | 20 (64.5%)             | 30 (61.2%)            | 0.81 |
| Use of BA (etanercept)           | 4 (12.9%)              | 4 (8.2%)              | 0.70 |

BMI: body mass index; WHI: waist-to-hip index; DAS28: Disease Activity Score in 28 joints; NSAIDs: non-steroidal anti-inflammatory drugs; DISMD: disease-modifying drug; BA: biological agent; NA: not available. Qualitative variables are expressed as percentages (%), and quantitative variables are expressed as mean values and standard deviations. Quantitative variables were compared using Student’s t-test for independent samples, and qualitative variables were compared using the chi-square test.

Table 5. Regression analysis assessing the association of independent variables with the development of increased body FM.

| Prediction criterion   | Method: introduction | IC95% | p   |
|------------------------|----------------------|-------|-----|
| Age, years             | 1.05                 | 0.98–1.12 | 0.12 |
| Disease duration, years| 1.06                 | 0.96–1.15 | 0.24 |
| DAS28                  | 1.03                 | 0.57–1.86 | 0.92 |
| Use of corticoids      | 1.36                 | 0.30–6.15 | 0.70 |
| DISMD therapy          | 0.27                 | 0.03–2.45 | 0.24 |

FM: fat mass; OR: odds ratio; IC95%: interval of confidence at 95%; DAS28: Disease Activity Score in 28 joints; DISMD: disease-modifying drug. Covariants included in the analysis corresponded to those with biological feasibility for developing body FM percentage. The model was adjusted for age and disease duration.
scores. The multivariate analysis, which was adjusted for age and disease duration, of the biological feasibility variables yielded no risk association for these variables.

Among the limitations of this study, we found that the sample size and the power analysis were not calculated, resulting in a small final sample size that could miss low mean disease activity differences. Its cross-sectional nature impaired us from identifying variations between FM percentage and disease activity measurements in the follow-up; these factors could modify the decrease in inflammatory activity and increase FM. We planned the study with a dichotomized value for FM according to Frankenfield et al., and unfortunately, we could not convert the DAS28 values to other scores.

In addition, body composition assessment via BIA is not the standard method of measurement; however, when tested against the reference measurement method of hydrostatic weighing, BIA values were found to correlate with this standard measurement by 90%.

In addition, we decided to use the ACR 1987 RA criteria because of the long disease durations in several cases that were extending before the ACR 2010 RA criteria became available, thus leading to a lower sensitivity for early RA cases. Regardless disease activity and health assessment measurements, we did not include the SDAI (Simplified Disease Activity Index), CDAI (Clinical Disease Activity Index), and HAQ (Health Assessment Questionnaire).

The factors potentially contributing to the differences found in the literature-reported studies include physical activity and its relationship with disease activity, resulting in less time spent performing physical activity, and thus the greater the disease activity. Other factors include the time between the FM and LM measurements as well as the presence of metabolic syndrome and even cardiovascular diseases. These factors, together with adipokines, could influence the distribution of FM percentage.

Conclusion

This article shows the lack of a relationship between disease activity as measured by DAS28 levels and FM percentage. As a significant issue, because the group of studied patients was composed of both incident and prevalent cases of rheumatoid arthritis, more longitudinal studies of incident cases are required to clarify the factors that could modify the relationship between DAS28 values and FM percentages.

Acknowledgements

The authors thank Editage (www.editage.com) for English language editing.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical approval

Ethical approval for this study was obtained from the Institutional Review board from CLIES 1301 (R-2016-1301-94).

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was partially financed by a research grant (FIS/IMSS/PROT/G16/1581).

Informed consent

Written informed consent was obtained from all subjects before the study.

ORCID iDs

Guadalupe Mendoza-Vázquez https://orcid.org/0000-0001-8562-6042
Sandra Guzmán-Silahua https://orcid.org/0000-0002-8751-2994
Arnulfo Hernán Nava-Zavala https://orcid.org/0000-0003-3061-521X

References

1. Rall LC and Roubenoff R. Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. Rheumatology 2004; 43(10): 1219–1223.
2. Ajeganova S, Andersson ML, Hafstrom I, et al. Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: a long-term followup from disease onset. Arthritis Care Res 2013; 65(1): 78–87.
3. Oranskiy SP, Yeliseyeva LN, Tsanaeva AV, et al. Body composition and serum levels of adiponectin, vascular endothelial growth factor, and interleukin-6 in patients with rheumatoid arthritis. Croat Med J 2012; 53(4): 350–356.
4. Burgos-Vargas R, Catoggio LJ, Galarza-Maldonado C, et al. Current therapies in rheumatoid arthritis: a Latin American perspective. Reumatol Clin 2013; 9(2): 106–112.
5. Pelaez-Ballestas I, Sanin LH, Moreno-Montoya J, et al. Epidemiology of the rheumatic diseases in Mexico: a study of 5 regions based on the COPCORD methodology. J Rheumatol Suppl 2011; 86: 3–8.
6. Engvall IL, Brismar K, Hafstrom I, et al. Treatment with low-dose prednisolone is associated with altered body composition but no difference in bone mineral density in rheumatoid arthritis patients: a controlled cross-sectional study. Scand J Rheumatol 2011; 40(3): 161–168.
7. Stavropoulos-Kalinoglou A, Metsios GS, Smith JP, et al. What predicts obesity in patients with rheumatoid arthritis? An investigation of the interactions between lifestyle and inflammation. Int J Obes 2010; 34(2): 295–301.
8. Mirpourian M, Salesi M, Abdolahi H, et al. The association of body mass index with disease activity and clinical response to combination therapy in patients with rheumatoid arthritis. J Res Med Sci 2014; 19(6): 509–514.
9. Ibn Yacoub Y, Amine B, Laatiris A, et al. Prevalence of overweight in Moroccan patients with rheumatoid arthritis and its relationships with disease features. Clin Rheumatol 2012; 31(3): 479–482.
10. Salamat MR, Shanci A, Salamat AH, et al. Anthropometric predictive equations for estimating body composition. Adv Biomed Res 2015; 4: 34

11. Lee BJ and Yim MH. Comparison of anthropometric and body composition indices in the identification of metabolic risk factors. Sci Rep 2021; 11: 9931.

12. Garcia-Poma A, Segami MI, Mora CS, et al. Obesity is independently associated with impaired quality of life in patients with rheumatoid arthritis. Clin Rheumatol 2007; 26(11): 1831–1835.

13. Giles JT, Bartlett SJ, Andersen R, et al. Association of body fat with C-reactive protein in rheumatoid arthritis. Arthritis Rheum 2008; 58(9): 2632–2641.

14. Toussirot E, Michel F, Bind D, et al. The role of leptin in the pathophysiology of rheumatoid arthritis. Life Sci 2015; 140: 29–36.

15. Dessein PH, Woodiwiss AJ, Norton GR, et al. Rheumatoid arthritis is associated with reduced adiposity but not by unfavorable major cardiovascular risk factor profiles and enhanced carotid atherosclerosis in black Africans from a developing population: a cross-sectional study. Arthritis Research & Therapy 2013; 15: R96.

16. Belmonte Serrano MA. Is the DAS28 score the most adequate method to estimate activity in rheumatoid arthritis? Clinimetric considerations and simulations scenarios. Reumatol Clin 2008; 4(5): 183–190.

17. Balsa A. Defining remission in rheumatoid arthritis: new ACR/EULAR criteria. Reumatol Clin 2011; 6S3: S12–S15.

18. Curtis JR, McVie T, Mikuls TR, et al. Clinical response within 12 weeks as a predictor of future low disease activity in patients with early RA: results from the TEAR trial. J Rheumatol 2013; 40(5): 572–578.

19. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31(3): 315–324.

20. Prevoo ML, van’t Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38(1): 44–48.

21. Cruz JRA, Luis M-R, Carlos M-P, et al. Protocolo de valoración de la composición corporal para el reconocimiento médico-deportivo. Documento de consenso del grupo español de cineantropometría de la Federación Española de Medicina del Deporte. Arch Med Deport 2009; 16: 166–179.

22. Frankenfield DC, Rowe WA, Cooney RN, et al. Limits of body mass index to detect obesity and predict body composition. Nutrition 2001; 17(1): 26–30.

23. Tanita Corporation of America. BC-533 InnerScan body composition monitor. Patent U.S. Reissue Patent No. 37,954, USA, 2005.

24. World Health Organization. Physical status: the use of and interpretation of anthropometry (Report of a WHO expert committee). Geneva: WHO, 1995.

25. Marfell-Jones M, Olds T, Stewart A, et al. International standards for anthropometric assessment. Shenzhen, China: Shenzhen University Press, 2006.

26. Dahloqvist SR, Enstrand S, Berglin E, et al. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy. Scand J Rheumatol 2006; 35(2): 107–111.

27. Engvall IL, Tengstrand B, Brismar K, et al. Inflimixab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months. Arthritis Res Ther 2010; 12(5): R197.

28. Raterman HG, Levels H, Voskuyl AE, et al. HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab. Ann Rheum Dis 2013; 72(4): 560–565.

29. Toussirot E, Grandclement E, Gaugler B, et al. Serum adipokines and adipose tissue distribution in rheumatoid arthritis and ankylosing spondylitis. Front Immunol 2013; 4: 453.

30. Heimans L, Van den Broek M, de Cessie S, et al. Association of high body mass index with decreased treatment response to combination therapy in recent-onset rheumatoid arthritis patients. Arthritis Care Res 2013; 65(8): 1235–1242.

31. Gremses E, Carleto A, Padovan M, et al. Obesity and reduction of the response rate to anti-tumor necrosis factor alpha in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res 2013; 65: 94–100.

32. Oner SY, Volkan O, Oner C, et al. Serum leptin levels do not correlate with disease activity in rheumatoid arthritis. Acta Reumatol Port 2015; 40: 50–54.

33. Metsios GS, Stavropoulos-Kalinoglou A, Douglas KM, et al. Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia. Rheumatology 2007; 46(12): 1824–1827.

34. Di Carlo M, Salaffi F, Gremses E, et al. Body mass index as a driver of selection of biologic therapy in rheumatoid arthritis: results from the US-CLARA Study. Eur J Intern Med 2019; 66: 57–61.

35. Sandberg MEC, Bengtsson C, Källberg H, et al. Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis. Ann Rheum Dis 2014; 73(11): 2029–2033.

36. Cojocaru M, Cojocaru IM, Silosi I, et al. Extra-articular manifestations in rheumatoid arthritis. Acta Rheumatol Port 2010; 5: 286–291.

37. Peters MJ, Vis M, van Halm VP, et al. Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. Ann Rheum Dis 2007; 66(7): 958–961.

38. Hornberg K, Pomeroy J, Sandberg C, et al. Physical activity in rheumatoid arthritis: relationship to cardiovascular risk factors, subclinical atherosclerosis, and disease activity. Scand J Rheumatol 2020; 49(2): 112–121.